GLOBAL HEAD, JANSSEN BUSINESS DEVELOPMENT
Patrick Verheyen is Global Head, Janssen Business Development. In this role, Patrick leads the business development organization to identify, execute, integrate and manage global licensing, mergers & acquisitions (M&A), divestiture and out-licensing deals for the Janssen Pharmaceutical Companies of Johnson & Johnson. Patrick assumed this role in April 2015.
Prior to this, Patrick helped design and launch Johnson & Johnson Innovation and was the Head of Johnson & Johnson Innovation, London. This Innovation strategy has delivered a robust early-stage portfolio and has helped earn Johnson & Johnson a reputation as a preferred partner with external innovators, entrepreneurs and academic institutions.
Patrick joined Johnson & Johnson in 1986 at Janssen Pharmaceuticals in Beerse, Belgium. He has held several leadership roles within our Pharmaceuticals organization including Vice President, New Ventures, Pharmaceuticals, where he led an agile and diverse team who facilitated divestitures, established strategic collaborations and identified investments that provided Janssen with access to external innovation and early product flow. Patrick also served as Vice President, M&A, where he facilitated strategic collaborations and acquisitions including Crucell, Elan and Cougar Biotechnology, and established spin-out companies, including Movetis. Patrick has provided expertise on most of the major M&A deals in the biotech, specialty pharmaceutical and large capital space, and assessed various risk sharing and funding arrangements with Clinical Research Organizations, private equity groups and government institutions.
Before beginning his professional career, he studied bioengineering at the University of Leuven, Flanders, Belgium.